Novel ZEB2-BCL11B Fusion Gene Identified by RNA-Sequencing in Acute Myeloid Leukemia with t(2;14)(q22;q32) | Zendy

Synne Torkildsen | Zendy; Ludmila Gorunova | Zendy; Klaus Beiske | Zendy; Geir E. Tjønnfjord | Zendy; Sverre Heim | Zendy; Ioannis Panagopoulos | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Novel ZEB2-BCL11B Fusion Gene Identified by RNA-Sequencing in Acute Myeloid Leukemia with t(2;14)(q22;q32)

Author(s) -

Synne Torkildsen,

Ludmila Gorunova,

Klaus Beiske,

Geir E. Tjønnfjord,

Sverre Heim,

Ioannis Panagopoulos

Publication year - 2015

Publication title -

plos one

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.99

H-Index - 332

ISSN - 1932-6203

DOI - 10.1371/journal.pone.0132736

Subject(s) - fusion transcript , exon , sanger sequencing , biology , myeloid leukemia , microbiology and biotechnology , fusion gene , chromosomal translocation , dna sequencing , gene , genetics , cancer research

RNA-sequencing of a case of acute myeloid leukemia with the bone marrow karyotype 46,XY,t(2;14)(q22;q32)[5]/47,XY,idem,+?4,del(6)(q13q21)[cp6]/46,XY[4] showed that the t(2;14) generated a ZEB2-BCL11B chimera in which exon 2 of ZEB2 (nucleotide 595 in the sequence with accession number NM_014795.3) was fused to exon 2 of BCL11B (nucleotide 554 in the sequence with accession number NM_022898.2). RT-PCR together with Sanger sequencing verified the presence of the above-mentioned fusion transcript. All functional domains of BCL11B are retained in the chimeric protein. Abnormal expression of BCL11B coding regions subjected to control by the ZEB2 promoter seems to be the leukemogenic mechanism behind the translocation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research